RT Journal Article
SR Electronic
T1 Treatment of Glioblastoma with Intravenous Taurolidine. First Clinical Experience
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1143
OP 1148
VO 24
IS 2C
A1 STENDEL, RUEDIGER
A1 PICHT, THOMAS
A1 SCHILLING, ANDREAS
A1 HEIDENREICH, JENS
A1 LODDENKEMPER, CHRISTOPH
A1 JÄNISCH, WERNER
A1 BROCK, MARIO
YR 2004
UL http://ar.iiarjournals.org/content/24/2C/1143.abstract
AB Background: Despite progress in diagnosis and therapy, the prognosis of patients with glioblastoma remains poor. Recently it has been found that the antibacterial agent taurolidine has a direct and selective antineoplastic effect on brain tumor cells by the induction of programmed cell death. This paper reports on intravenous taurolidine treatment in two patients with a progressive glioblastoma despite conventional therapy. Patients and Methods: Two male patients with histopathologically diagnosed glioblastoma were included. The tumors were progressive despite conventional therapy. Intravenous taurolidine treatment was initiated. Results: The neurological condition and quality of life improved in both patients such that they could be discharged for further outpatient treatment. Follow-up demonstrated partial remission of the tumor in both patients. However, both patients died about 4 months following the start of taurolidine treatment, from pneumonia and acute thrombembolism, respectively. Conclusion: Both patients achieved a transient, marked improvement in quality of life and partial tumor remission. There was a clear response to the taurolidine treatment. Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved